Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our modelOne out of the three major indices are trading lower today with the Dow Jones Industrial Average (^DJI) trading down 57 points (-0.4%) at 13,961 as of Wednesday, Feb. 13, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,624 issues advancing vs. 1,238 declining with 155 unchanged.The Drugs industry currently is unchanged today versus the S&P 500, which is unchanged. A company within the industry that increased today was Sanofi (SNY), up 0.9%.TheStreet Ratings group would like to highlight 3 stocks pushing the industry higher today:3. Pharmacyclics Incorporated (PCYC) is one of the companies pushing the Drugs industry higher today. As of noon trading, Pharmacyclics Incorporated is up $5.23 (7.4%) to $75.60 on heavy volume Thus far, 678,885 shares of Pharmacyclics Incorporated exchanged hands as compared to its average daily volume of 545,200 shares. The stock has ranged in price between $72.25-$75.95 after having opened the day at $74.86 as compared to the previous trading day's close of $70.37. Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Pharmacyclics Incorporated has a market cap of $4.9 billion and is part of the health care sector. The company has a P/E ratio of 50.5, above the S&P 500 P/E ratio of 17.7. Shares are up 22.4% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Pharmacyclics Incorporated a buy, no analysts rate it a sell, and 5 rate it a hold.TheStreet Ratings rates Pharmacyclics Incorporated as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Pharmacyclics Incorporated Ratings Report now.It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE
Latest Headlines about AZN
Latest from TheStreet Wire
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV